Recursion Pharmaceuticals Aktie News

It comes as no surprise that artificial intelligence is at the heart of the opportunity. This application of AI, in fact, is arguably one of the best uses of this young technology.

DraftKings' bulls were thrown an unexpected curveball, but this new competition doesn't carry the same brand-name cache. After years of development, Recursion Pharmaceuticals' AI-powered drug discovery technology should finally, firmly start proving its true value.

Recursion Pharmaceuticals lagged the market last year. The stock doesn't have significant catalysts on the horizon.

Recursion Pharmaceuticals, Inc. (RXRX) Presents at 28th Annual Needham Growth Conference Transcript

Tech giants Meta Platforms and Apple are capitalizing on their AI-related efforts. However, biotech upstart Recursion Pharmaceuticals' initiatives have yet to pay off.

Recursion Pharmaceuticals, Inc. (RXRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Salt Lake City, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today its CEO & President, Najat Khan, Ph.D., will present Tuesday, January 13, 10:30am PT at the upcoming 44th Annual J.P.

Recursion Pharmaceuticals, Inc. is upgraded to Buy, supported by promising REC-4881 data and strong institutional backing. REC-4881's Phase 1b/2 data in FAP show a 43% median polyp reduction, derisking the lead program ahead of pivotal studies. RXRX's $2.44bn market cap is justified by FAP opportunity, robust partnerships, and over $100m in milestone payments expected by end-2026.